- Home
- BCDA vs NURO Comparison
BCDA vs NURO Comparison
Compare BCDA & NURO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- NURO
- Stock Information
- Founded
- BCDA N/A
- NURO 1996
- Country
- BCDA United States
- NURO United States
- Employees
- BCDA N/A
- NURO N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- NURO Medical/Dental Instruments
- Sector
- BCDA Health Care
- NURO Health Care
- Exchange
- BCDA Nasdaq
- NURO Nasdaq
- Market Cap
- BCDA 7.9M
- NURO 8.2M
- IPO Year
- BCDA N/A
- NURO N/A
- Fundamental
- Price
- BCDA $2.68
- NURO $4.55
- Analyst Decision
- BCDA Strong Buy
- NURO
- Analyst Count
- BCDA 1
- NURO 0
- Target Price
- BCDA $25.00
- NURO N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- NURO 15.0K
- Earning Date
- BCDA 11-06-2024
- NURO 11-01-2024
- Dividend Yield
- BCDA N/A
- NURO N/A
- EPS Growth
- BCDA N/A
- NURO N/A
- EPS
- BCDA N/A
- NURO N/A
- Revenue
- BCDA $428,000.00
- NURO $4,383,614.00
- Revenue This Year
- BCDA $6.92
- NURO N/A
- Revenue Next Year
- BCDA N/A
- NURO N/A
- P/E Ratio
- BCDA N/A
- NURO N/A
- Revenue Growth
- BCDA 0.71
- NURO N/A
- 52 Week Low
- BCDA $1.96
- NURO $2.66
- 52 Week High
- BCDA $23.25
- NURO $5.60
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- NURO 65.06
- Support Level
- BCDA $2.39
- NURO $3.96
- Resistance Level
- BCDA $2.90
- NURO $4.69
- Average True Range (ATR)
- BCDA 0.18
- NURO 0.22
- MACD
- BCDA -0.00
- NURO 0.04
- Stochastic Oscillator
- BCDA 53.70
- NURO 82.35
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About NURO NeuroMetrix Inc.
NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.